NNNN Key Statistics, Chart & Performance
The current stock price of NNNN is 19.29 USD. In the past month the price decreased by -40.44%.
NNNN Technical Analysis
NNNN Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to NNNN. NNNN gets an excellent profitability rating and is at the same time showing great financial health properties.
NNNN Financial Highlights
Over the last trailing twelve months NNNN reported a non-GAAP Earnings per Share(EPS) of 0.04. The EPS increased by 57.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 42.53% | ||
| ROA | 31.55% | ||
| ROE | 34.72% | ||
| Debt/Equity | 0 |
NNNN Forecast & Estimates
NNNN Ownership
About NNNN
Company Profile
Anbio Biotechnology is a medical device company. The company is headquartered in Frankfurt, Hessen and currently employs 27 full-time employees. The company went IPO on 2025-02-19. The firm is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).
Company Info
ANBIO BIOTECHNOLOGY LTD
Friedrich-Ebert-Anlage 49
Frankfurt HESSEN DE
Employees: 27
Phone: 4916096247281
ANBIO BIOTECHNOLOGY LTD / NNNN FAQ
Can you describe the business of ANBIO BIOTECHNOLOGY LTD?
Anbio Biotechnology is a medical device company. The company is headquartered in Frankfurt, Hessen and currently employs 27 full-time employees. The company went IPO on 2025-02-19. The firm is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).
What is the current price of NNNN stock?
The current stock price of NNNN is 19.29 USD. The price decreased by -10.32% in the last trading session.
What is the dividend status of ANBIO BIOTECHNOLOGY LTD?
NNNN does not pay a dividend.
What is the ChartMill rating of ANBIO BIOTECHNOLOGY LTD stock?
NNNN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Which stock exchange lists NNNN stock?
NNNN stock is listed on the Nasdaq exchange.
What is the employee count for NNNN stock?
ANBIO BIOTECHNOLOGY LTD (NNNN) currently has 27 employees.
Can you provide the ownership details for NNNN stock?
You can find the ownership structure of ANBIO BIOTECHNOLOGY LTD (NNNN) on the Ownership tab.